Please login to the form below
Troxyca ER
This page shows the latest Troxyca ER news and features for those working in and with pharma, biotech and healthcare.
FDA panel backs Pfizer and Teva abuse-resistant painkillers
In the case of Troxyca ER, the inclusion of opioid blocker naltrexone is designed to achieve the same end result. ... The company secured rights to Troxyca ER (also known as ALO-02) when it acquired King Pharmaceuticals in 2010 for $3.6bn.
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars
- Cuttsy+Cuttsy awarded Gold accreditation by Investors in People
No results were found
PMHub
Aurora Healthcare Communications
We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
